News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
145–150
Matches
150
Sources here
4
Companies here
4
Search results Stored financial headlines

Active search

150 matching headlines

Ticker or company: AZNMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

AZN main company AZN main company AZN main company AZN main company
Sharemaestro market context Price below Trend Line 52 weeks +14.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

AZN main company AZN main company AZN main company AZN main company
Sharemaestro market context Price below Trend Line 52 weeks +14.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion …

AZN main company AZN main company
Sharemaestro market context Price below Trend Line 52 weeks -4.0% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AstraZeneca PLC (AZN) after its late-stage Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to meet its primary endpoint, causing a significant drop in the company's American Depositary Share (ADS) price. The …

AZN main company
Sharemaestro market context Price below Trend Line 52 weeks -1.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume

This article provides details on AstraZeneca Tokenized Stock (AZNX), a digital asset tracking AstraZeneca PLC's share price. It covers current price, market cap, trading volume, and market performance statistics. The article also explains AZNX's function as a tracker certificate within the xStocks ecosystem, offering …

AZN main company
Sharemaestro market context Price below Trend Line 52 weeks -1.4% AZN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context